SLC16A1 and lymphoma: AZD3965, a selective MCT1 inhibitor, has completed a phase I trial (NCT01791595) in patients with advanced solid tumors and lymphomas, demonstrating pharmacodynamic target engagement and acceptable safety in tumors characterized by high MCT1 and low MCT4 expression [110].